Terms: = Endocrine gland cancer AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315 AND Clinical Outcome
848 results:
1. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study.
Wagner T; Toft BG; Lauritsen J; Bandak M; Christensen IJ; Engvad B; Kreiberg M; Agerbæk M; Dysager L; Carus A; Rosenvilde JJ; Berney D; Daugaard G
Eur J Cancer; 2024 May; 202():114025. PubMed ID: 38531266
[TBL] [Abstract] [Full Text] [Related]
3. Relevance of mutations in protein deubiquitinases genes and
Pękul M; Szczepaniak M; Kober P; Rusetska N; Mossakowska BJ; Baluszek S; Kowalik A; Maksymowicz M; Zieliński G; Kunicki J; Witek P; Bujko M
Front Endocrinol (Lausanne); 2024; 15():1302667. PubMed ID: 38487343
[TBL] [Abstract] [Full Text] [Related]
4. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract] [Full Text] [Related]
5. Developing a novel image marker to predict the clinical outcome of neoadjuvant chemotherapy (NACT) for ovarian cancer patients.
Zhang K; Abdoli N; Gilley P; Sadri Y; Chen X; Thai TC; Dockery L; Moore K; Mannel RS; Qiu Y
Comput Biol Med; 2024 Apr; 172():108240. PubMed ID: 38460312
[TBL] [Abstract] [Full Text] [Related]
6. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
7. Locally advanced pancreatic cancer: Is surgical palliation associated with improved clinical outcome relative to medical palliation?
Kramer SP; Tonelli C; Luchette FA; Swanson J; Abdelsattar Z; Cohn T; Baker MS
Am J Surg; 2024 Apr; 230():73-77. PubMed ID: 38350746
[TBL] [Abstract] [Full Text] [Related]
8. Impact of a mobile health intervention based on multi-theory model of health behavior change on self-management in patients with differentiated thyroid cancer: protocol for a randomized controlled trial.
Jiang Y; Sun X; Jiang M; Min H; Wang J; Fu X; Qi J; Yu Z; Zhu X; Wu Y
Front Public Health; 2024; 12():1327442. PubMed ID: 38282759
[TBL] [Abstract] [Full Text] [Related]
9. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
10. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3.
Schadeck J; Oberg HH; Peipp M; Hedemann N; Schamel WW; Bauerschlag D; Wesch D
Front Immunol; 2023; 14():1286097. PubMed ID: 38259448
[TBL] [Abstract] [Full Text] [Related]
11. Long Non-Coding RNAs: Bridging cancer-Associated Thrombosis and clinical outcome of Ovarian cancer Patients.
Marques IS; Tavares V; Savva-Bordalo J; Rei M; Liz-Pimenta J; de Melo IG; Assis J; Pereira D; Medeiros R
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203310
[TBL] [Abstract] [Full Text] [Related]
12. HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Koskela H; Li Y; Joutsiniemi T; Muranen T; Isoviita VM; Huhtinen K; Micoli G; Lavikka K; Marchi G; Hietanen S; Virtanen A; Hautaniemi S; Oikkonen J; Hynninen J
Gynecol Oncol; 2024 Jan; 180():91-98. PubMed ID: 38061276
[TBL] [Abstract] [Full Text] [Related]
13. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract] [Full Text] [Related]
14. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract] [Full Text] [Related]
15. Subarachnoid hemorrhage due to pituitary adenoma apoplexy-case report and review of the literature.
Yildiz Y; Lauber A; Char NV; Bozinov O; Neidert MC; Hostettler IC
Neurol Sci; 2024 Mar; 45(3):997-1005. PubMed ID: 37872321
[TBL] [Abstract] [Full Text] [Related]
16. Optimal Follow-up of Incidental Pancreatic Cystic Lesions without Worrisome Features: clinical outcome after Long-term Follow-up.
Ahn DW; Lee SH; Choi JH; Cho IR; Jang DK; Paik WH; Jeong JB; Ryu JK; Kim YT
Gut Liver; 2024 Mar; 18(2):328-337. PubMed ID: 37840221
[TBL] [Abstract] [Full Text] [Related]
17. Response of Locally Advanced Pancreatic cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and clinical outcome.
Sharma NR; Lo SK; Hendifar A; Othman MO; Patel K; Mendoza-Ladd A; Verco S; Maulhardt HA; Verco J; Wendt A; Marin A; Schmidt CM; diZerega G
Pancreas; 2023 Mar; 52(3):e179-e187. PubMed ID: 37782888
[TBL] [Abstract] [Full Text] [Related]
18. Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
[TBL] [Abstract] [Full Text] [Related]
19. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
20. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
[TBL] [Abstract] [Full Text] [Related]
[Next]
